Cleveland State University

EngagedScholarship@CSU
Chemistry Faculty Publications

Chemistry Department

6-2016

Novel Protein Disulfide Isomerase Inhibitor with Anticancer
Activity in Multiple Myeloma
Sergei Vatolin
Cleveland Clinic

James G. Phillips
Cleveland Clinic

Babal K. Jha
Cleveland Clinic

Shravya Govindgari
Cornell University

Jennifer Hu
Case Western Reserve University

Follow
this
andfor
additional
works
at: https://engagedscholarship.csuohio.edu/scichem_facpub
See next
page
additional
authors
Part of the Medicinal-Pharmaceutical Chemistry Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Vatolin, Sergei; Phillips, James G.; Jha, Babal K.; Govindgari, Shravya; Hu, Jennifer; Grabowski, Dale;
Parker, Yvonne; Lindner, Daniel J.; Zhong, Fei; Distelhorst, Clark W.; Smith, Mitchell R.; Cotta, Claudiu; Xu,
Yan; Chilakala, Sujatha; Kuang, Rebecca R.; Tall, Samantha; and Reu, Frederic J., "Novel Protein Disulfide
Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma" (2016). Chemistry Faculty Publications.
475.
https://engagedscholarship.csuohio.edu/scichem_facpub/475

This Article is brought to you for free and open access by the Chemistry Department at EngagedScholarship@CSU.
It has been accepted for inclusion in Chemistry Faculty Publications by an authorized administrator of
EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.

Authors
Sergei Vatolin, James G. Phillips, Babal K. Jha, Shravya Govindgari, Jennifer Hu, Dale Grabowski, Yvonne
Parker, Daniel J. Lindner, Fei Zhong, Clark W. Distelhorst, Mitchell R. Smith, Claudiu Cotta, Yan Xu, Sujatha
Chilakala, Rebecca R. Kuang, Samantha Tall, and Frederic J. Reu

This article is available at EngagedScholarship@CSU: https://engagedscholarship.csuohio.edu/scichem_facpub/475

Novel Protein Disulfide Isomerase Inhibitor with
Anticancer Activity in Multiple Myeloma
Sergei Vatolin, James G. Phillips, Babal K. Jha, Shravya Govindgari, Jennifer Hu,
Dale Grabowski, Yvonne Parker, Daniel J. Lindner, Fei Zhong, Clark W. Distelhorst,
Mitchell R. Smith, Claudiu Cotta, Yan Xu, Sujatha Chilakala, Rebecca R. Kuang,
Samantha Tall, and Frederic J. Reu

Introduction
Despite progress, multiple myeloma remains largely incurable,
recruiting relapses from genetically heterogeneous multiple mye
loma subclones (1, 2). Cytopenias from cumulative treatment
toxicity and refractory multiple myeloma limit therapeutic
options and lifespan creating need for bone marrow sparing
approaches effective against genetically highly variable myeloma
cell populations.
Defense against stress misfolded proteins exert on the endo
plasmic reticulum (ER) has been identified as Achilles heel of

multiple myeloma (3). Proteins destined for secretion enter the
ER in an incompletely folded state and factors commonly found
in cancer, like augmented protein synthesis, nutrient deficiency,
and hypoxia increase them or impair their folding exerting ER
stress (4). In multiple myeloma, high protein synthesis related to
neoplastic behavior is amplified by plasma cell program activa
tion yielding the highest protein secretion rate known in mam
malian biology (5). Furthermore, secreted antibodies have com
plex folding needs involving correct arrangement of multiple
intra- and intermolecular disulfide bonds (5, 6). If misfolded
proteins accumulate in the ER gradually induction of the tran
scription factor CHOP (C∕EBP homologous protein) triggers
suicide (4) whereas acute misfolding events like severe hypoxia
cause apoptosis via opening of ER calcium channels (7). One way
cells attempt to evade such fate is by transport of misfolded ER
proteins into the cytoplasm for ubiquitination and proteasomal
degradation (8, 9). Interference with disposal of naturally occur
ring misfolded antibodies appears critical for clinical success of
the proteasome inhibitor bortezomib in multiple myeloma (10,
11), suggesting a blockade of the folding mechanism could
further improve multiple myeloma therapy. Only the family of
protein disulfide isomerases (PDI), which contains 17 members
with 1-4 active CXXC or CXXC-like motifs (12), can accomplish
correct arrangement of disulfide bonds in the ER through reduc
tase, oxidase, and isomerase functions.
To streamline selection of anti-multiple myeloma drug candi
dates for further study, we chose a mechanistically unbiased
approach and filtered compounds by assessment in one

multilayered assay modeling major barriers to clinical success;
liver metabolism, need for diffusion, transient exposure, myelo
ma-supporting niche, and bone marrow toxicity. The lead com
pound (CCF642) had broad anti-multiple myeloma activity, was
effective in vivo, and appeared to act, at least in part, by inhibition
of PDI through a novel mechanism. Here we describe the discov
ery and initial characterization of CCF642.

Materials and Methods
Cells
RPMI 8226, NCI-H929, MM1.S, MM1.R, U266, Jeko-1, Rec-1,
Mino, JVM-2, SU-DHL-6, SU-DHL-16, I<562, K<G-1, GDM-1, and
HS-5 were from ATCC (authenticated there by STR). KMS-12-PE
and KMS-12-BM were from JCRB (authenticated there by STR)
and JJN-3 from DSMZ (authenticated there by multiplex PCR of
minisatellite markers). 5TGMl-luc mouse multiple myeloma
cells were kindly provided by Dr. Babatunde O. Oyajobi, Univer
sity of Texas Health Science Center at San Antonio (San Antonio,
TX), where this cell line was discovered and characterized (1316). All of the above cells were kept in culture for less than 6
months including expansion for aliquot freezing. HRMM.09 cells
were established from blood of a patient with secondary plasma
cell leukemia under Institutional Review Board (IRB)-approved
consent in our laboratory. MMl.S-luc, HRMM.09-luc, and NCIH292-luc were transduced with firefly luciferase lentivirus (Qiagen), not further authenticated, but used within 6 months after
luciferase expression confirmation. Anti-CD138 magnetic beadpurified peripheral blood plasma cells from two patients with
secondary plasma cell leukemia (sPCL-l, -2) who consented to an
IRB-approved sample collection protocol were used after 4 weeks
in culture and one Ficoll density centrifugation to remove dead
cells. Normal bone marrow mononuclear (NLBM) cells were from
discarded bags of bone marrow grafts from healthy stem cell
donors under an IRB-approved consent waiver. Human multiple
myeloma cells were grown in RPMI 1640, 5TGM1-luc in IMDM,
HS-5 in DMEM, and NLBM cells in RPMI supplemented with 25%
(v∕v) of supernatant removed from confluent HS-5 cell cultures;
all media was supplemented with 10% FBS, penicillin G (50 units/
mL), and streptomycin (50 μg∕mL). All cells cultured at 37°C, 5%
CO2 in humidified air.
Primary screen
A total of 30,335 chemically diverse small molecules were
screened for anti-multiple myeloma activity in MM 1 .S cells using
a single-step cellular ATP quantitation assay (Supplementary
Table S1 and Supplementary Methods).
Multilayered (sandwich) in vivo model
HS-5 bone marrow stromal cells were grown to confluence on
semipermeable bottoms of 24-well Transwell inserts (Corning),
then MMl.S-luc cells were added and cocultured overnight. The
next day, drug candidate was suspended into C57BL∕KaLwRij
mouse liver homogenate (preparation in Supplementary Meth
ods), incubated at 37°C for 30 minutes, then mixed with 35-40°C
warm low gelling temperature liquid agarose (Sigma-Aldrich),
and immediately dispensed into 24-well plates where it was
allowed to solidify at room temperature for 30 minutes. NLBM
cells were layered on top and left there, whereas HS-5∕MMl.S-luc
cell containing inserts were moved after 1 to 3 hours with about
25% of the drug-equilibrated media in them into drug-free liver/

agarose/media wells to decrease concentrations of drugs by esti
mated 75% once a new equilibrium is reached, assuming no liver
metabolism occurs. Three to 4 days later, multiple myeloma
luciferase activity was measured after addition of firefly D-luciferin, 0.5 mg/mL (Gold Biotechnology), and viability of aspirated
NLBM cells was assessed by trypan blue exclusion using Vicell flow
(Beckman Coulter).

Medicinal chemistry
CCF642, biotinylated CCF642 (B-CCF642), and CCF642COOH were synthesized in our laboratories. Synthetic schemes
and graphs confirming their identity by 1H-NMR and mass
spectrometry are in Supplementary Methods and Fig. S1,
respectively.
PDI activity
PDI activity was measured according to a published protocol
using di-eosin-diglutathione (di-E-GSSG) as pseudo substrate for
sensitive assessment of PDFs reductase activity (17) with minor
modifications and details in Supplementary Methods.
Computational modeling and molecular dynamics
The computational model used the reduced PDI (NP_000909.2)
crystal structure (18), as binding ofbiotinylated CCF642 to PDI was
enhanced after reduction with dithiothreitol (DTT). Docking of
CCF642 on PDI (PDB ID: 4EKZ) used Autodock 4.1 (in Autodock
Tools 1.5.2). Binding energy calculations used CHARMM force field
in Discovery Studio 1.3 pipeline (Accelrys, Inc.). Final image
processing and electrostatic surface potential calculation used
Pymol (www.pymol.org).

Single-cell cytoplasmic calcium measurements
MM 1 .S cells were loaded with Fura 2-AM and dynamic changes
in cytoplasmic calcium concentration were measured by singlecell digital imaging as described previously in detail (19).
PDIA1 site-directed mutagenesis
Human cDNA clone NM_000918 (Origene) was subcloned
from pCMV6-XL4 into pT7CFEl-CHis (Thermo Fisher Scientific)
for site-directed mutagenesis (primer sequences in Supplemen
tary Methods) using QuikChange II XL (Agilent Technologies).
Proteins were purified with His-tagged purification miniprep-kit
(Clontech).

Protein S-nitrosylation
Protein S-nitrosylation was investigated via biotin switch meth
od using Cayman Chemical kit (cat.# 10006518) according to
manufacturer's instructions.
Genotoxicity screen
Genotoxicity screen used SOS chromotest kit with S9 rat liver
enzymes (ebpi) according to manufacturer's instructions.

Animal experiments
Animal experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Animals of the NIH,
and conducted under an approved Institutional Animal Care and
Use Committee protocol. C57BL∕KaLwRij mice (Harlan Laborato
ries) of 6 to 8 weeks of age were injected with 5TGM1-luc cells via
tail vein the day before drug treatments were started. CCF642
was administered as albumin formulation intraperitoneally,

Figure 1.

Schema of small-molecule screening algorithm. The in vivo model exposes
NLBM constantly to small molecule (sm)-emitting liver, whereas luciferaseexpressing MM1.S-luc cells, grown on resistance-conferring HS-5 bone
marrow stroma cells in Transwell inserts, are exposed for 1 to 3 hours before
they are placed with drug-equilibrated insert media (about 25% of well
volume) into wells containing drug-free liver and NLBM with 75% small
molecule-free media to simulate rapid single-dose clearance and the natural
microenvironment. Three to 4 days later, drug-exposed NLBM cells are
aspirated and analyzed by trypan blue flow cytometry, whereas MM1.S-luc
survival is assessed by luminescence. The primary cytotoxicity screen and
multiple myeloma cell line panel uses conventional constant small molecule
exposure, with cellular ATP measurement and trypan blue flow cytometry
after 3 to 4 days as readout of surviving cells, respectively.

bortezomib in PBS subcutaneously. Life imaging using Xenogen
IVIS CCD was performed 7 minutes after subcutaneous injection of
luciferin (Gold Biotechnology). Statistical analysis used JMP 10.0.X
software (SAS Institute, Inc.). Retro-orbital plexus blood draws
were done after isoflurane (3%) inhalation anesthesia and com
plete blood counts obtained on Hemavet 950FS (Drew Scientific),
which gives mouse reference values; plasma biochemical tests were
analyzed on cobas c311 (Roche Diagnostics) with gender specific
biochemical reference values from C57B1∕6J mice (20) as reference.

Results
Mechanistically unbiased discovery of antimyeloma compound
CCF642
To identify new clinically translatable treatments for the incur
able cancer multiple myeloma that disrupt critical programs for
this malignancy while sparing normal bone marrow, we used a
mechanistically unbiased algorithm on a library of 30,335 small
molecules (Fig. 1). The first step tested for anti-multiple myeloma
activity. It identified 225 compounds that suppressed cellular ATP
in MM1.S cells to ≤30% of vehicle control at <5 μmol∕L after 3 to
4 days (Fig. 1 and Supplementary Table S1). Step two sought to
filter these 225 agents for clinical promise in terms of relative
tolerance by NLBM and ability to overcome pharmacokinetic and

pharmacodynamic barriers to anti-multiple myeloma activity.
Emitted from agarose-embedded liver homogenate that was able
to reduce the activity of hepatically metabolized bortezomib
(Supplementary Fig. S2); only three drug candidates demonstrated
promising anti-multiple myeloma activity in a setup that included
resistance conferring HS-5 bone marrow stroma cells (21) as niche
and a method to decrease drug concentrations through nonhepatic means after 90 minutes by transfer of MMl.S-luc/HS-5
containing semipermeable inserts into drug-free liver/agarose/
media containing wells. None of the three hits inhibited the
number of surviving NLBM cells by more than 30%, although
they were exposed to drug-emitting liver constantly for 4 days
(Figs. 1 and 2B). Bortezomib, known to berelatively well tolerated
by normal bone marrow at doses needed to control multiple
myeloma, had a similar therapeutic window in this assay (Fig. 2B).
In the third step, we tested whether compounds targeted
programs of general importance in multiple myeloma via cyto
toxicity assessment in a cell line panel. All three hits of step 2 had
sub- or low micromolar IC50 (<5 μmol∕L) against all of at least
seven genetically heterogeneous multiple myeloma cell lines
tested per compound using trypan blue flow cytometry with
constant exposure over 72 hours (Fig. 2C). CCF642 was most
potent with submicromolar IC50 in 10 of 10 multiple myeloma
cell lines tested (Fig. 2C).
Step four asked whether the in vivo model indeed yielded
molecules with in vivo activity. To this end, we used an aggressive
syngeneic mouse model of myeloma (15) that causes typical
myeloma bone disease and death of C57BL∕KaLwRij mice about
1 to 2 months after tail vein injection of luciferase expressing
5TGM1 cells (5TGMl-luc). 5TGMl-luc mouse multiple myeloma
cells were included in the otherwise human multiple myeloma
cell line panel (Fig. 2C) to ensure the target was expressed in mice
as well. Limited solubility could be addressed by dissolving
DMSO stock of CCF642 and CCF1172 into albumin solution,
which had no toxicity as vehicle on multiple myeloma cells and
did not affect potency of hits against multiple myeloma cells in
vitro, but the best solution we identified for CCF1118, 0.8%
Tween-20 in sterile water, did not allow dosing above 4 mg∕kg.
With these limitations in mind, CCF642 at 10 mg/kg intraperitoneally three times a week yielded most convincing therapeutic
effects, significantly prolonging life of 5TGMl-luc-bearing mice
and suppressing 5TGM1 -luc growth as determined by life imaging
(Fig. 2D). We therefore concentrated on CCF642 and initially
evaluated cytotoxicity against other hematologic malignancies,
which revealed similar IC50 in ontogenetically related lymphoma,
whereas a three-cell line screening sample of myeloid neoplasia
showed more varied responsiveness. Primary cells from patients
with refractory myeloma who developed secondary plasma cell
leukemia (sPCL) also had IC50 below 1 μmol/L, whereas three
separate NLBM samples confirmed NLBM tolerance up to 6.75
μmol∕L, the maximal dose tested (Supplementary Fig. S3).
Next, we compared CCF642 to the most potent FDA-approved
upfront drug for myeloma, bortezomib. CCF642 at 10 mg/kg
intraperitoneally three times a week significantly improved lifespan of mice compared with albumin vehicle. Bortezomib given
at the MTD for this mouse strain (0.6 mg/kg subcutaneously twice
a week) yielded similar prolongation of life, not statistically
different from CCF642 (P = 0.18, log-rank test), and life imaging
on day 23 documented comparable significant suppression of
5TGMl-luc growth. Treatments appeared to be well-tolerated on
the basis of normal behavior and stable weights (Fig. 3A-C). To

explore safety further, blood after 15 and 28 days of treatment
from five additional 5TGM1 -luc-bearing mice per time point was
obtained to screen for toxicity on bone marrow (blood counts),
liver (alanine aminotransferase, ALT), kidney (creatinine), and
effects on glucose metabolism. Except for asymptomatic increase
of neutrophils, parameters remained within reference range after
CCF642 (Fig. 3D). Culture of 5TGMl-luc and MMl.S-luc cells in
bortezomib-containing media over 6 months increased the IC50
toward this drug but not toward CCF642 in both cell lines,
suggesting CCF642 may prove useful in the context of bortezomib
resistance and acts via a different mechanism (Fig. 4).
An active biotinylated analogue identifies PDI as CCF642 target
To identify the target of CCF642, we introduced a biotin moiety
at its 4-methoxy group (Fig. 5A) expecting this was not the target
interaction site since a commercially available unsubstituted phe
nyl analog retained anti-multiple myeloma activity, although IC50
in MM1.S was increased from 0.25 to 1.8 μmol∕L. Biotinylated
CCF642 (B-CCF642) also had higher IC50 (2.9 μmol/L), but at
6.75 μmol/L, MM1.S survival was comparable to CCF642 (<2Oo∕o
at 72 hours), suggesting it may act intracellularly but enter less
well. Streptavidin immunohistochemistry confirmed entry into
the cytoplasm of MM1.S (Fig. 5B). Treatment of MM1.S cells with
B-CCF642 followed by SDS-PAGE and biotin staining suggested
covalent interactions are formed with a main band at around 60
kDa (Supplementary Fig. S4). Mass spectrometry of streptavidinbead purified protein lysates from B-CCF642-treated and untreat
ed MM 1 .S cells run through SDS-PAGE and cut from a correspond-

ing area of the gel (50-70 kDa) revealed protein disulfide isom
erase Al (PD1A1, protein disulfide isomerase precursor) as most
abundant protein found only after treatment. Two other PDI
family members, PDIA3 (protein disulfide isomerase precursor
A 3) and PD1A4 (protein disulfide isomerase precursor A 4), were
also only identified in treated samples (Supplementary Table S2).
Incubation of recombinant PDI with B-CCF642 with or with
out prior CCF642 incubation followed by SDS-PAGE and biotin
stain confirmed PDI as common target (Fig. 5C). B-CCF642 also
covalently bound to recombinant PDIA3 but not to BSA used in
the animal treatment formulation for its solubility-enhancing
properties (Fig. 5C).To test whether CCF642 affects PDI function,
we performed di-E-GSSG assays, which measure PDI's reducing
capacity (17), and compared inhibition to known PDI inhibitors
PACMA31 (22) and LOC14 (23). CCF642 at 1 μmol/L inhibited
reduction of di-E-GSSG about as much as 100 μmol/L of LOC14
or PACMA 31 (Fig. 5D). Accordingly, the anti-multiple myeloma
activity against three exemplary multiple myeloma cell lines was
most pronounced with CCF642 (Fig. 5E). These observations
raised the question of how CCF642 inhibits PDI.

CCF642-PDI binding model
Computational docking argued against covalent binding to
active site cysteine used by PACMA 31 and all other known
covalently binding PDI inhibitors (22, 24), as CCF642 could not
be approximated any closer than 5 Angstrom. The amino group of
adjacent conserved functionally relevant lysine (25), with 2.8
Angstrom came close enough to the carbonyl group of CCF642

Figure 3.

CCF642 has in vivo anti-multiple
myeloma activity comparable with
bortezomib. A, CCF642 and
bortezomib significantly (log-rank
test) extend survival in the aggressive
5TGM1-luc∕C57BL∕KaLwRij mouse
model of myeloma (6 males, 7 females
per treatment group). B, in vivo
imaging on day 23 confirms antimultiple myeloma activity of CCF642
and bortezomib (BTZ) with
significantly (Student t test) lower
luminescence. Top, in vivo images;
bottom, signal intensity. Error bars,
SEM. C, weight of mice was not
affected by treatments. D, results of
blood draws from 5 separate male
and female 5TGM1-luc-bearing
C57BL∕KaLwRij mice after 2 and
4 weeks of treatment, respectively
(reference values). Error bars, SD.

to propose a covalent reaction (Fig. 5F). B-CCF642 binding
studies on PDIA1 mutants targeting both active sites were con
sistent with this computational hypothesis. Replacement oflysine
with glutamic acid completely blocked, whereas the NH2 side
chain containing glutamine allowed weak binding; replacement
of cysteine with serine had no effect (Fig. 4G). Definitive crystal
lographic binding studies are beyond the scope of this article but
clearly needed since a covalent reaction with lysine would likely
require its deprotonation and it is not known whether this occurs
during PDFs redox reactions or upon entry of CCF642 into its
enzymatic pocket. Computationally, additional non-covalent
interactions were predicted between NO2 of the nitrothiophene
moiety of CCF642 and the NH2 side chain of glutamine adjacent
to lysine (Q402 in Fig. 5F). All PDI family members pulled out
from multiple myeloma cells with B-CCF642 have NH2 side chain
containing amino acids at that site, suggesting they may be

important for PDI activity and for binding of B-CCF642. Accord
ingly, substitution of the NO2 group in CCF642 with COOH
reduced anti-PDI activity (Fig. 6A) and binding to PDI as assessed
by competition with B-CCF642 (Fig. 6B). To investigate whether
the NO2 group might be released from CCF642 and inhibit PDI
via S-nitrosylation, we incubated recombinant PDI with CCF642
or S-nitrosogluthathione and tested for nitrosylated PDI using the
biotin switch method (26). We found no evidence for s-nitrosyla
tion of PDI with CCF642, whereas the positive control effectively
caused this change (Fig. 6C). Furthermore, the bacterial SOS
chromotest found no evidence for genotoxicity of CCF642 up to
20 μmol/L with or without prior liver enzyme incubation (Fig.
6D), arguing against nonspecific DNA toxicity, which could occur
with NO2 release or other DNA toxic effects. The reaction between
CCF642 and CGHCI< motifs of PDI family members therefore
likely leaves CCF642 intact. The putatively novel mechanism of

Figure 4.

Growth in bortezomib (BTZ) does not
cause CCF642 resistance. Six-month
exposure to bortezomib followed
by at least 3 days off increased the
IC50 toward this drug in two multiple
myeloma cell lines, whereas it did not
increase IC50 for CCF642. The
x-axis displays multiples of the IC50 in
parent cells required to reduce trypan
blue-negative cells at 72 hours for
each drug as average of three
independent experiments. Error
bars, SD.

PDI inhibition, higher potency than known PDI inhibitors, and
favorable safety signals from NLBM, animal studies, and the
bacterial genotoxicity screen warranted pursing the mechanism
of antimyeloma action of CCF642 further.

Acute ER stress with apoptosis-inducing calcium release in
myeloma by CCF642
Treatment of myeloma cells with CCF642, PACMA 31, or
LOC14 at doses in the upper clinically achievable range leads to
accumulation of misfolded proteins in the ER as documented
by dimerization of PERK via phosphorylation (3, 4) and
oligomerization of IRE-lα (27), most pronounced after
CCF642, but suggesting they may all be able to inhibit PDI
in vivo (Fig. 7A). Increase of the proapoptotic unfolded protein
response (UPR) mediator CHOP is evident within 30 minutes
for all compounds but interestingly XBPl-s, a critical transcrip
tion factor for mediating the adaptive UPR (3, 4), undergoes a
time-dependent decline that correlates with PARP cleavage,
suggesting it may be degraded by apoptotic enzymes along
with misfolded protein sensors PERK and IRE-lα (Fig. 7A). To
investigate whether XBP1 activation via unconventional splic
ing of its cytoplasmic mRNA by dimerized IRE-lα is intact we
performed RT-PCR (Fig. 7B). In these experiments, MM1.S cells
were used, as it was known that despite baseline ER stress,
spliced XBP1 mRNA is not detectable in them without exog
enous stressors (28). CCF642 caused IREl-α dimerization
within 15 minutes, peaking at 1 hour, and within 2 hours,
spliced XBP1 mRNA could be detected confirming lREl-α
dimers were functionally intact (Fig. 7B) and followed a similar
time course as the other main ER stress sensor, PERK (Fig. 7C).
Nuclear fractions demonstrated decrease of the transcription
factor XBP-ls within 15 minutes compromising defense against
ER stress, probably due to acute induction of apoptotic path
ways by CCF642 (Fig. 7A and E). As kinetics of apoptotic
pathway induction were faster than predicted for the transcrip
tion factor CHOP, we hypothesized acute increase of misfolded
proteins might trigger apoptosis-inducing release of ER calcium
stores. Indeed, single-cell cytosolic calcium measurements in
MM1.S and NLBM after 3 μmol/L CCF642 revealed selective
increase in MM1.S that followed a similar time course as ER
stress sensor (PERK, IREl-α) and apoptotic pathway kinetics,
whereas NLBM did not respond noticeably with ER stress
sensors (total PERK and IRE-lα antibodies yielded no signals,
shown PERK is faint) and minimally cleaved caspase-3 (Fig.
7B-D and F). BAPTA AM, a cell-permeable calcium chelator

dose, dependently delayed caspase-3 and PARP cleavage in
MM1.S by CCF642 (Fig. 7E), suggesting calcium release con
tributed to apoptosis.

Discussion
Here we report the discovery of a novel antimyeloma drug
candidate with inhibitory function on the only enzyme family
capable of folding disulfide-rich secreted proteins like antibodies
through a mechanistically unbiased screening algorithm, which
simulated key barriers to in vivo success.
Efficacy of lead CCF642 in a syngeneic mouse myeloma
model (Figs. 2 and 3) comparable to fully optimized FDAapproved first-line proteasome inhibitor bortezomib (Fig. 3)
confirms that an anti-multiple myeloma assay with highly
simplified modeling of liver, non-hepatic clearance, and bone
marrow (Figs. 1 and 2B) can identify promising drug candidates.
CCF642 was one of three structurally distinct compounds from a
30,335 small-molecule screening algorithm demonstrating
desired anti-multiple myeloma activity without substantial
bone marrow toxicity in this assay that we applied as lowthroughput manual screen on 225 confirmed active anti-mul
tiple myeloma small molecules. The two other compounds (Fig.
2) were less convincing during pilot in vivo experiments, but this
may in part be related to difficulties with their formulation
(CCF1118) or lower potency (CCF1172). The described setup
with lymphoid and myeloid growth factor secreting HS-5 bone
marrow stromal cells as niche, documented to confer resistance
not only to multiple myeloma (21, 29) but also to myeloid and
other lymphoid cells (30-32), should be applicable to a variety
of bone marrow cancers but would require adjustment for solid
tumors. Compared with reported cancer-niche screens (33),
growth in semipermeable inserts expands modeling options like
simulation of non-hepatic clearance without disruption of cell
contacts by transfer into drug-free media. Use of inserts further
enables compartmentalized NLBM growth and inclusion of liver
homogenate. Applied to chemical library compounds it will not
mimic in vivo pharmacokinetic behavior but has the potential to
enrich for agents with higher likelihood of in vivo activity by
filtering for stability toward liver enzymes, ability to diffuse
(through agarose and cell layers), and suppress cancer on niche
with adjustable bolus-like or constant exposure. Our results
suggest it may further enable selection of agents without sub
stantial adverse effects on the bone marrow (Fig. 3D). If others
confirm our findings and automation is achieved, it may

Figure 5.

PDI is a target of CCF642. A, biotinylated CCF642 (B-CCF642). B, streptavidin IHC confirms entry of B-CCF642 into the cytoplasm of MM1.S cells. C, CCF642 and BCCF642 compete for binding to recombinant PDIA1, quantified by densitometry of immunoblot images normalized to background and PDI AB signals (left).
The right immunoblot panel shows no evidence for covalent B-CCF642 binding to BSA after 30-minute incubation but to PDIA3. Ponceau S stain was used
to document protein loading. D, time-dependent inhibition of di-E-GSSG reduction by PDI with CCF642 or known PDI inhibitors PACMA 31 and LOC14
normalized to spontaneous di-E-GSSG reduction. E, reduction of trypan blue-negative cells at 72 hours in three multiple myeloma cell lines by CCF642 and known PDI
inhibitors at up to 6.75 μmol∕L. F, electrostatic surface representation of CCF642 docked onto PDI (Protein Data Bank ID: 4EKZ) as predicted by Autodock 4.
Energy minimization suggested covalent binding may occur to conserved lysine K401, where the carbonyl group of CCF642 is predicted to reach within 2.8 A of its
amino group, whereas distances of 4.58 and 5.83 A between the oxygen atoms of the NO2 group of CCF642 and the NH2 group of glutamine 402 suggest
noncovalent interaction could occur at this site. A similar situation is predicted for the other active site CGHCK motif and for other PDIs sharing this motif.
G, biotin stain and anti-His AB immunoblot after a 30-minute incubation with 5 μmol/L B-CCF642 of recombinant wild-type PDIA1 and mutants that have both active
sites (a and a') mutated as indicated shows B-CCF642 binding is dependent on lysine but not on cysteine. All experimental results under this figure are
representative of at least three independent experiments. Error bars, SD.

Figure 6.

The NO2 group of CCF642 is important for PDI inhibition but does not lead to S-nitrosylation or genotoxicity. A, structure of CCF642 analog with COOH instead of NO2
(top), which is about 10× less potent than parent CCF642 in the di-E-GSSG PDI activity assay (bottom). B, CCF642-COOH competes with B-CCF642 for
PDI binding but less potently than CCF642 by densitometric analysis (Fig. 5C). C, PDI was incubated with 10 μmol/L CCF642 or 10 mmol/L S-nitrosogluthathione for 1
hour before processing according to the biotin switch method that exchanges S-nitrosylated sulfhydryl groups with biotin. D, SOS chromotest bacteria
(ebpi, inc.) induce β-galactosidase in response to genotoxic stress and constitutively express alkaline phosphatase. The graph shows increase in β-galactosidase∕
alkaline phosphatase signals = SOS activity after 2-hour incubation at indicated doses for the genotoxic agent 4NQ0 and for 2AA, which becomes genotoxic
after liver enzyme incubation. CCF642, with or without liver incubation, did not increase SOS activity over untreated control. Results are representative
of three independent experiments. Error bars, SD.

streamline cancer drug discovery by reducing unsuccessful costly
animal experiments.
Like many small molecules from diversity libraries, CCF642has
limited aqueous solubility, creating challenges when moving
from in vitro to in vivo where higher volume of distribution
requires administration of more concentrated drug. After standard
solvents used for intravenous formulations failed to keep CCF642
in solution, we explored albumin, an abundant plasma protein
with hydrophobic and hydrophilic surfaces. Albumin is FDAapproved as carrier for paclitaxel in Abraxane and bovine as well as
human albumin has been used in mice effectively for drug
delivery (34, 35). Albumin-dissolved CCF642 could be given
intravenously without injection reactions in mice, but for ease
of administration, we chose the intraperitoneal route and saw
promising efficacy without obvious toxicity. Albumin could gen
erally be considered for clinical translation but we anticipate
medicinal chemistry optimization will enable a less expensive
formulation. Respective efforts will aim for crystallographic con
firmation ofthe putatively novel interaction with PDI (Fig. 5F and
G) to allow rational design and analog pharmacophore testing.
The thiazolidinedione-like structure of CCF642 and its ability to
increase cytosolic calcium in myeloma cells suggest special atten
tion will need to be placed on liver, mitochondrial, and cardiac
safety in the analog selection process. Preliminary and limited
safety analyses of CCF642 in myeloma-bearing mice found no

evidence for liver toxicity or fluid accumulation anti-diabetic
PPAR-activating thiazolidinediones can cause, but mild decrease
of blood sugar (Fig. 3D) reinforces the need for vigilance and
suggests a possible off-target effect of CCF642 will need to be
investigated. Stable cytosolic calcium in NLBM cells after CCF642
(Fig. 7D) argues against broad nonspecific mitochondrial toxicity
but does not obviate the need for further investigation into
possible effects of optimized analogs on liver or heart. Further
more, asymptomatic increase of neutrophils in intraperitoneal
albumin-CCF642-treated mice (Fig. 3D) suggests optimizing
formulation to avoid delayed precipitation that may have subclinically irritated peritoneal membranes and investigating pos
sible alternate mechanisms will be important in drug develop
ment. Although the CCF642 scaffold raises outlined safety con
cerns, our preliminary analyses suggest it may yield an optimized
analog that satisfies safety mandates for clinical translation.
Success of the proteasome inhibitor bortezomib has estab
lished protein homeostasis as valid target in oncology, especially
for lymphoid malignancies (11, 36) but multiple myeloma
remains incurable costing estimated 11,240 lives in 2015 in the
United States (SEER). CCF642, consistent with its effect on
proteostasis by PDI inhibition (Figs. 5 and 7), had potent activity
in the submicromolar IC50 range on multiple myeloma and
lymphoma cell lines while so far limited evaluations in myeloid
neoplasia revealed more varied and less pronounced effects

Figure 7.

Acute ER stress with apoptosis-inducing calcium release in myeloma by CCF642. A, PDI inhibitors increase PERK dimerization by phosphorylation and IRE1-α
oligomerization within 30 minutes in KMS-12-PE confirming accumulation of misfolded ER proteins. Proapoptotic ER stress signaling via CHOP induction is
intact with all PDI inhibitors but XBP-1s, a transcription factor mediating adaptive ER stress responses, decreases in a temporal pattern that correlates with PARP
cleavage, suggesting breakdown along with PERK and IRE1-α. PDI staining documents comparable loading. B, immunoblots and RT-PCR of MM1.S whole
cell, nuclear, and cytoplasmic fractions show XBP1 splicing (s) of cytoplasmic unspliced (u) mRNA in response to CCF642 is intact and detectable about 1 hour after
dimerization of IRE1-α peaks. Nuclear XBP1-s protein undergoes a decline that correlates with PARP cleavage (E) in this cell line as well. C, PERK dimers in
MM1.S cells treated with CCF642 confirm increase of misfolded proteins in the ER of MM1.S cells after 15 minutes. D, MM1.S and NLBM cells were loaded with
the intracellular calcium indicator Fura-2 AM, and cytoplasmic calcium concentration was continuously recorded following addition (arrow) of 3 μmol/L
CCF642 or DMSO vehicle. Each trace is average calcium concentration in 86 to 89 cells. E, immunoblots show that pretreatment of MM1.S cells with intracellular
calcium chelator BAPTA AM for 1 hour before 3 μmol/L CCF642 delayed caspase-3 and PARP cleavage. F, immunoblot of NLBM cells after CCF642 treatment
reveals minimal increase in PERK dimers and minimal caspase 3 cleavage. Results are representative of at least three independent experiments per panel.

(Supplementary Fig. S3). The central role of PDI for ER produc
tivity and stress reduction suggests exocrine cancers and histolo
gies with high levels of ER stress should be tested in future studies.
Two leading PDI inhibitors have remained preclinical so far;
PACMA 31 covalently binds to active site cysteines of PDI and
has shown promise in ovarian cancer (22), whereas LOC14 was
found to have antiapoptotic function on nerve cells in a model of
Huntington disease and binds noncovalently at nanomolar con
centration but requires high micromolar doses for PDI inhibition
in the insulin aggregation assay (23), which measures its reducing
potency (24). To date, no reliable method for measuring PDI
activity in cells has been described and in intro assays used in drug
discovery poorly reproduce PDI physiology where cysteine oxi
dation, reduction, and isomerization of disulfide bonds has to be
accomplished in short sequence and is influenced by additional
enzymes, like Erol-α (37) that restore oxidative potential of PDI
required for immunoglobulin folding (5). Therefore, current in
vitro PDI activity assays mainly establish that a drug candidate can
affect PDI function but not how effectively its versatile enzymatic
potential is impaired in vivo or how profoundly restoration by
Erol-α is affected. We chose the most sensitive in vitro PDI activity
assay to quantify inhibition and then evaluated whether the most
upstream expected consequence of PDI inhibition occurred in
cells, sensing of misfolded ER proteins by PERK and IREl-α.
CCF642 was more potent than known PDI inhibitors in the in
vitro assay against myeloma cells (Fig. 5) and when assessed for
ability to increase misfolded ER proteins in multiple myeloma
cells, but the latter experiments that used doses in the upper
range of generally clinically achievable (3 μmol/L) suggested that
all PDI inhibitors may reach their target in vivo (Fig. 7A). For
CCF642, the only PDI inhibitor where this dose was above the
IC50 against multiple myeloma cells and against PDI in vitro, this
was followed by acute induction of apoptosis, faster than expected
from induction of the proapoptotic ER stress mediator CHOP.
Further studies suggested that calcium release, possibly from rapid
accumulation of misfolded ER proteins, was at least partially
responsible (Fig. 7). Detailed studies on the mechanism of
calcium release by CCF642 in multiple myeloma are beyond the
scope of this article but might reveal additional targets or inter
ference with interaction of PDI with calcium-regulating proteins
like calreticulin (38).
In summary, results suggest a straightforward assay that simu
lates important barriers to in vivo success of anti-multiple mye

loma compounds can yield candidates promising for clinical
translation. While its first lead may act through mechanisms in
addition to PDI inhibition, it is so far the most promising antimultiple myeloma PDI-inhibiting compound. Fully defining its
interaction with PDI through crystallography may enable devel
opment of optimized specific PDI inhibitors with potentially
broader oncology application.
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